Efficacy and safety of micafungin as an empirical antifungal agent for febrile neutropenic patients with hematological diseases

Acta Haematologica

Volumn 124, Issue 2, 2010, Pages 92-97

  Park, Joon Seong ^a   Kim, Dong Hwan ^b   Choi, Chul Won ^c   Jeong, Seong Hyun ^a   Choi, Jin Hyuk ^a   Kim, Kihyun ^b   Kim, Seok Jin ^b   Jung, Chul Won ^b   Yang, Deok Hwan ^d   Jang, Jun Ho ^b  

^a Ajou University School of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Korea University College of Medicine   (South Korea)

^d Chonnam National University   (South Korea)

Author keywords

Hematological diseases; Micafungin; Neutropenic fever

Indexed keywords

ASPARTATE AMINOTRANSFERASE; MICAFUNGIN; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ECHINOCANDIN; LIPOPEPTIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEMATOLOGIC DISEASE; HUMAN; HYPERBILIRUBINEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SEPTIC SHOCK; SIDE EFFECT; URTICARIA; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; COMPLICATION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MIDDLE AGED; MYCOSES; NEUTROPENIA; PROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ECHINOCANDINS; FEMALE; FEVER; HUMANS; IMMUNOCOMPROMISED HOST; LEUKEMIA, MYELOID, ACUTE; LIPOPEPTIDES; LYMPHOMA; MALE; MIDDLE AGED; MYCOSES; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77954680894     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315558     Document Type: Article

References (22)

1. Andriole VT: Infections with Aspergillus species. Clin Infect Dis 1993; 17(suppl 2) : S481-S486.
2. Pannuti C, Gingrich R, Pfaller MA, Kao C, Wenzel RP: Nosocomial pneumonia in patients having bone marrow transplant. Attributable mortality and risk factors. Cancer 1992; 69: 2653-2662.
3. Vartivarian SE, Anaissie EJ, Bodey GP: Emerging fungal pathogens in immunocom-promised patients: classification, diagnosis, and management. Clin Infect Dis 1993; 17(suppl 2):S487-S491.
4. Empiric antifungal therapy in febrile granu-locytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. Am J Med 1989; 86:668-672.
5. Pizzo PA: The value of protective isolation in preventing nosocomial infections in high risk patients. Am J Med 1981; 70:631-637.
6. Barnes PD, Marr KA: Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. Br J Haematol 2007; 139: 519-531.
7. Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ: Epidemiology, outcomes, and costs of invasive aspergillosis in immuno-compromised children in the United States, 2000. Pediatrics 2006; 117:e711-e716.
8. Hatano K, Morishita Y, Nakai T, Ikeda F: An-tifungal mechanism of fk463 against Candida albicans and Aspergillus fumigatus. J Antibiot (Tokyo) 2002; 55:219-222.
9. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, Pow-derly WG, Hyslop N, Kauffman CA, Cleary J, Mangino JE, Lee J: Antifungal susceptibility survey of 2000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003; 47: 3149-3154.
10. Tawara S , Ikeda F, Maki K , Morishita Y, Otomo K, Teratani N, Goto T, Tomishima M, Ohki H, Yamada A, Kawabata K, Takasugi H, Sakane K, Tanaka H, Matsumoto F, Ku-wahara S: In vitro activities of a new lipopep-tide antifungal agent, FK463, against a vari-et y of clinically important fungi. Antimicrob Agents Chemother 2000; 44: 57-62.
11. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Munoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE: Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-1821.
12. Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, Schwarer AP, Novitzky N, Boehme A, Chwetzoff E, De Beule K: Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001; 135:412-422.
13. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwar t z C, Bodenstei ner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy And Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-771.
14. Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC: A multicenter, randomized trial of fluconazole versus ampho-tericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000; 108:282-289.
15. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, de-Pauw BE: Caspofungin versus liposomal am-photericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 20 04; 351: 1391-1402.
16. Shimizu T, Ochiai H, Asell F, Shimizu H, Saitoh R, Hama Y, Katada J, Hashimoto M, Matsui H, Taki K, Kaminuma T, Yamamoto M, Aid a Y, Ohashi A, Ozawa N: Bioi nfor mat-ic s research on inter-racia l d if ference in drug metabolism. 1. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab Phar-macokinet 2003; 18:48-70.
17. Kohno S, Masaoka T, Yamaguchi H, Mori T, Urabe A, Ito A, Niki Y, Ikemoto H: A multi-center, open-label clinical study of micafun-gin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004; 36: 372-379.
18. Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, Sekhon JS, Freire A, Ramasubramanian V, Demeyer I, Nucci M, Leelarasamee A, Jacobs F, Decruyenaere J, Pittet D, Ullma nn AJ, Os-trosky-Zeichner L, Lortholary O, Koblinger S, Diekmann-Berndt H, Cornely OA: Mi-cafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369:1519-1527.
19. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, Mullane KM, Vazquez J, Anaissie EJ, Lipton J, Jacobs P, van Rensburg JH, Rex JH, Lau W, Facklam D, Buell DN: International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005; 24:654-661.
20. Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, Vazquez JA, Dupont BF, Horn DL, Ostrosky-Zeichner L, Reboli AC, Suh B, Digumarti R, Wu C, Kovanda LL, Arnold LJ, Buell DN: Micafungin versus ca-spofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45:883-893.
21. Tamura K, Urabe A, Yoshida M, Kanamaru A, Kodera Y, Okamoto S, Maesaki S, Masa-oka T: Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hemato-logical disorders. Leuk Lymphoma 2009; 50: 92-100.
22. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Schuster M, Re-boli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdiere M, Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J: Voriconazole compared with liposomal am-photericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-234.